Clinical Trials Sector Scorecard - Thematic Research

Clinical Trials Sector Scorecard - Thematic Research

Summary

Some of the key challenges that the pharma industry faces when running clinical trials include complex and inefficient trial design, low patient recruitment and retention rates, delays leading to high costs, and data integrity and privacy issues.

To overcome these issues, the industry must invest in technologies that improve clinical trial processes. This includes those that facilitate the implementation of virtual trials, a key trend in the pharma industry as a result of the ongoing disruption to clinical trials due to COVID-19 lockdowns and social distancing measures. These technologies include remote patient monitoring (RPM), telemedicine, wearables, and mobile health. In addition, the use of emerging technologies such as cloud computing, cybersecurity, and blockchain allow for patient data from trials to be stored and analyzed safely, whereas artificial intelligence (AI) can be used to enhance trial design and recruitment.

Developing rare disease drugs and improving trial participant diversity are seen as two important aspects of social sustainability. In rare disease, there is often little incentive to develop therapies as the patient populations are so small. However, orphan drug designations provide many benefits such as enhanced regulatory processes, fee waiving, tax benefits, and market exclusivity.

Our thematic scoring methodology is designed to identify tomorrow’s leaders rather than today’s incumbents, based on their competitive position in the 10 most important themes impacting the landscape.

Scope

• this Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trials sector over the next two to four years.
• These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
• The scorecard includes 54 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
• The methodology contains detailed information on what data sources were used to generate the thematic scores for each company.

Reasons to Buy

• Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
• Understand which key themes should be addressed to drive share price.
• Understand which companies are best positioned for success within critical themes and why.
• Learn which companies have underinvested in key themes and are most vulnerable to disruption.
• Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
• Help identify future winners and losers in drug development to inform partnership strategies.